Abdel Raouf Samar M, Ibrahim Taiseer R, Abdelaziz Lobna A, Farid Mohamed I, Mohamed Salem Y
Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
J Gastrointest Cancer. 2021 Mar;52(1):90-98. doi: 10.1007/s12029-019-00344-4.
Colorectal carcinoma (CRC) is the third most common human cancer. Twist, a basic helix-loop-helix (bHLH) transcription factor, is an epithelial-mesenchymal transition ((EMT) inducer that has been involved in carcinogenesis and chemoresistance. Also, the enhancer of Zeste homolologue2 (EZH2), a member of the polycomb group of genes, had been associated with poor prognosis in several malignancies.
To evaluate the expression of Twist1 and EZH2 in colon carcinoma in Egyptian patients and its relation to clinicopathological parameters, prognosis, and survival.
Twist1 and EZH2 expressions were evaluated immunohistochemically in 50 cases of colorectal tumors (12 colon adenomas and 38 colon carcinomas) and 20 samples from normal colonic mucosa.
The expression of Twist1 and EZH2 was significantly higher in colon adenoma and carcinoma than that in normal colonic mucosa (P < 0.05). Twist1 and EZH2 expressions were associated with decreased tumor differentiation, advanced stage, and lymph node metastasis. Twist1 and EZH2 expressions were significantly related to 3-year disease-free survival (P = 0.005 and 0.002 respectively) and 3-year overall survival (P = 0.045 and 0.039, respectively).
Twist1 and EZH2 may serve as prognostic predictors for colon carcinoma and may have a potential role as therapeutic targets in patients with colon carcinoma in the future.
结直肠癌（CRC）是人类第三大常见癌症。Twist是一种碱性螺旋-环-螺旋（bHLH）转录因子，是一种上皮-间质转化（EMT）诱导因子，参与了肿瘤发生和化疗耐药。此外，多梳基因家族成员Zeste同源物2（EZH2）增强子与多种恶性肿瘤的不良预后相关。
评估埃及结肠癌患者中Twist1和EZH2的表达及其与临床病理参数、预后和生存的关系。
采用免疫组织化学方法评估50例结直肠肿瘤（12例结肠腺瘤和38例结肠癌）和20例正常结肠黏膜样本中Twist1和EZH2的表达。
Twist1和EZH2在结肠腺瘤和癌中的表达显著高于正常结肠黏膜（P < 0.05）。Twist1和EZH2的表达与肿瘤分化降低、晚期和淋巴结转移相关。Twist1和EZH2的表达与3年无病生存率（分别为P = 0.005和0.002）和3年总生存率（分别为P = 0.045和0.039）显著相关。
Twist1和EZH2可能作为结肠癌的预后预测指标，未来可能在结肠癌患者中作为治疗靶点发挥潜在作用。
